In June 2021, interim results of the randomized, double-blind OlympiA clinical trial were published, demonstrating the efficacy of olaparib for treating breast cancer in the adjuvant setting.2 Patients with pathogenic or likely pathogenic gBRCAm and nonmetastatic, ERBB2-negative primary breast cancer were randomized to receive twice-daily oral olaparib or placebo for 1 year following completion of definitive local treatment and neoadjuvant or adjuvant chemotherapy. The gene discussed is ERBB2; the disease is breast carcinoma.